Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant CHICAGO and TORONTO,
March 22, 2022
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant CHICAGO and TORONTO,
Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study Peyote
Tasmanian ketamine study to treat chronic pain patients About 60% of patients with chronic pain
Blackhawk’s MindBio Therapeutics Invests NZ$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets After finding its DMT
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder Novamind (NM) began a
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of
XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone Vancouver, Canada, and
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation PharmaTher (PHRM) was granted a US patent
Healing my worth: Sarah’s story Despite having a supportive family and a healthy lifestyle, Sarah
Psychedelic therapy for depression still effective one year later Johns Hopkins researchers followed up with
MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients TORONTO, ON / February
Filament Health and Cybin Therapeutics Announce Approval for Phase II Clinical Trial for Depression Trial
Perception study may explain promising depression therapy Our brains are constantly making predictions about the
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With
Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin
Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat
Filament Health and Cybin Therapeutics Announce Licensing Agreement Filament will license PEX010, its proprietary botanical
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program atai
MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia MYND’s Second